AR069135A1 - Compuesto de alfa-(n-sulfonamido) acetamida como un inhibidor de produccion de peptido beta amiloide - Google Patents
Compuesto de alfa-(n-sulfonamido) acetamida como un inhibidor de produccion de peptido beta amiloideInfo
- Publication number
- AR069135A1 AR069135A1 ARP080104770A ARP080104770A AR069135A1 AR 069135 A1 AR069135 A1 AR 069135A1 AR P080104770 A ARP080104770 A AR P080104770A AR P080104770 A ARP080104770 A AR P080104770A AR 069135 A1 AR069135 A1 AR 069135A1
- Authority
- AR
- Argentina
- Prior art keywords
- sulfonamide
- acetamide
- alpha
- composite
- amyloid peptide
- Prior art date
Links
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 title 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98411807P | 2007-10-31 | 2007-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069135A1 true AR069135A1 (es) | 2009-12-30 |
Family
ID=40193955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104770A AR069135A1 (es) | 2007-10-31 | 2008-10-30 | Compuesto de alfa-(n-sulfonamido) acetamida como un inhibidor de produccion de peptido beta amiloide |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8084477B2 (enExample) |
| EP (3) | EP2295417B1 (enExample) |
| JP (1) | JP5460605B2 (enExample) |
| KR (1) | KR20100075575A (enExample) |
| CN (2) | CN102718689A (enExample) |
| AR (1) | AR069135A1 (enExample) |
| AT (1) | ATE502022T1 (enExample) |
| AU (1) | AU2008319122A1 (enExample) |
| BR (1) | BRPI0818837A2 (enExample) |
| CA (1) | CA2704360A1 (enExample) |
| CL (1) | CL2008003271A1 (enExample) |
| CO (1) | CO6270332A2 (enExample) |
| CY (2) | CY1112337T1 (enExample) |
| DE (1) | DE602008005636D1 (enExample) |
| DK (2) | DK2205575T3 (enExample) |
| EA (2) | EA201171439A1 (enExample) |
| ES (2) | ES2361283T3 (enExample) |
| HR (2) | HRP20110219T1 (enExample) |
| IL (1) | IL205406A0 (enExample) |
| MX (1) | MX2010004319A (enExample) |
| NZ (1) | NZ584545A (enExample) |
| PE (1) | PE20091394A1 (enExample) |
| PL (2) | PL2295417T3 (enExample) |
| PT (2) | PT2295417E (enExample) |
| SG (2) | SG174043A1 (enExample) |
| SI (2) | SI2205575T1 (enExample) |
| TW (1) | TW200927099A (enExample) |
| WO (1) | WO2009058552A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE430727T1 (de) | 2001-12-20 | 2009-05-15 | Bristol Myers Squibb Co | Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren |
| US8093276B2 (en) * | 2007-10-31 | 2012-01-10 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| US8044077B2 (en) * | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| MX2011009271A (es) * | 2009-03-19 | 2011-09-26 | Bristol Myers Squibb Co | Nuevo compuesto de alfa-(n-sulfonamido)acetamida como inhibidor de la produccion del peptido beta amiloide. |
| US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| TW201043269A (en) * | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| CN104072408B (zh) * | 2010-03-12 | 2016-09-14 | 日本曹达株式会社 | 含有吡啶环的化合物、及卤代甲基吡啶衍生物以及四唑基肟衍生物的制造方法 |
| WO2012040444A2 (en) * | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Treatment of patients with incipient alzheimer's disease |
| EP2643299B1 (en) * | 2010-11-22 | 2016-06-22 | Noscira, S.A. | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions |
| JP2015529250A (ja) | 2012-09-21 | 2015-10-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | フルオロアルキルジベンゾジアゼピノン化合物 |
| CN104797584A (zh) | 2012-09-21 | 2015-07-22 | 百时美施贵宝公司 | 作为notch抑制剂的三环杂环化合物 |
| CN104822677A (zh) | 2012-09-21 | 2015-08-05 | 百时美施贵宝公司 | 氟烷基-1,4-苯并二氮杂*酮化合物 |
| WO2014047369A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinone compounds |
| CN103058913B (zh) * | 2012-12-13 | 2015-09-30 | 江苏弘和药物研发有限公司 | 5-氯异吲哚酮的合成方法 |
| CN104163784B (zh) * | 2014-06-20 | 2019-01-08 | 湖南天地恒一制药有限公司 | 一种奥拉西坦的合成工艺 |
| RU2757276C2 (ru) | 2016-12-16 | 2021-10-12 | Пайплайн Терапьютикс, Инк. | Способы лечения кохлеарной синаптопатии |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| CN107935957B (zh) * | 2017-12-02 | 2020-08-21 | 江苏仁明生物科技有限公司 | 一种合成高纯度沙坦侧链ttbb的方法 |
| MX2020012495A (es) | 2018-06-01 | 2021-02-15 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas. |
| CN108640886A (zh) * | 2018-08-01 | 2018-10-12 | 余锋 | 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法 |
| TW202115114A (zh) | 2019-06-24 | 2021-04-16 | 瑞士商諾華公司 | 針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法 |
| CN113466367B (zh) * | 2021-06-25 | 2023-04-14 | 深圳万乐药业有限公司 | 乌苯美司原料药中α-苯乙胺杂质检测方法 |
| CN113816874B (zh) * | 2021-10-30 | 2024-01-26 | 大连双硼医药化工有限公司 | 一种合成4-氰基-2-氟苄醇的工艺方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5274094A (en) | 1990-08-15 | 1993-12-28 | British Bio-Technology Limited | Production of heterobicyclic containing benzene sulfonamides |
| GB9202791D0 (en) | 1992-02-11 | 1992-03-25 | British Bio Technology | Compounds |
| US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| PL326700A1 (en) | 1995-11-17 | 1998-10-26 | Warner Lambert Co | Sulphonamide-based inhibitors of intercellular substance metaloproteinases |
| RU2202540C2 (ru) | 1996-07-22 | 2003-04-20 | Монсанто Компани | Тиолсульфонамидные ингибиторы металлопротеазы |
| JPH11343279A (ja) | 1998-03-16 | 1999-12-14 | Shionogi & Co Ltd | スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤 |
| NZ512306A (en) | 1999-01-27 | 2003-10-31 | American Cyanamid Co | Acetylenic sulfonamide thiol tace inhibitors |
| US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| EP1159263A1 (en) * | 1999-02-26 | 2001-12-05 | Merck & Co., Inc. | Novel sulfonamide compounds and uses thereof |
| US6541467B1 (en) * | 2000-04-14 | 2003-04-01 | Corvas International, Inc. | Thrombin inhibitors having a lactam at P3 |
| US20020115640A1 (en) * | 2000-11-30 | 2002-08-22 | Claiborne Akiyo K. | Farnesyltransferase inhibitors |
| US20040179277A1 (en) * | 2001-12-14 | 2004-09-16 | Stallard Charles R | Precisely aligned lens structure and a method for its fabrication |
| ATE430727T1 (de) | 2001-12-20 | 2009-05-15 | Bristol Myers Squibb Co | Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren |
| PL372090A1 (en) * | 2002-02-28 | 2005-07-11 | Astrazeneca Ab | Chemical compounds |
| ES2286345T3 (es) * | 2003-03-20 | 2007-12-01 | Santhera Pharmaceuticals (Schweiz) Ag | Derivados de piperidina y piperazina substituidos como moduladores del receptor de melanocortina-4. |
| JP2006522126A (ja) | 2003-03-31 | 2006-09-28 | ワイス | βアミロイド生産のフルオロ含有およびトリフルオロアルキル含有複素環スルホンアミド阻害物質およびその誘導体 |
| US7144894B2 (en) | 2004-09-23 | 2006-12-05 | Bristol-Myers Squibb Company | Sulfonamide bicyclic compounds |
| BRPI0707742A2 (pt) | 2006-02-17 | 2011-05-10 | Wyeth Corp | processo para preparar um composto |
| US7687666B2 (en) | 2006-02-17 | 2010-03-30 | Wyeth | Methods for preparing sulfonamide substituted alcohols and intermediates thereof |
| WO2008112249A1 (en) | 2007-03-13 | 2008-09-18 | Trustees Of Columbia University In The City Of New York | Synergistic interaction of notch-1 inhibitors with glucocorticoids |
| WO2009005688A2 (en) | 2007-06-29 | 2009-01-08 | Trustees Of Columbia University In The City Of New York | Activating mutations in notch-1 |
| US8093276B2 (en) | 2007-10-31 | 2012-01-10 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| US8044077B2 (en) * | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
-
2008
- 2008-10-10 US US12/249,180 patent/US8084477B2/en active Active
- 2008-10-14 AU AU2008319122A patent/AU2008319122A1/en not_active Abandoned
- 2008-10-14 MX MX2010004319A patent/MX2010004319A/es active IP Right Grant
- 2008-10-14 CN CN201210178082XA patent/CN102718689A/zh active Pending
- 2008-10-14 EA EA201171439A patent/EA201171439A1/ru unknown
- 2008-10-14 HR HR20110219T patent/HRP20110219T1/hr unknown
- 2008-10-14 EP EP10190591A patent/EP2295417B1/en not_active Not-in-force
- 2008-10-14 PL PL10190591T patent/PL2295417T3/pl unknown
- 2008-10-14 ES ES08843687T patent/ES2361283T3/es active Active
- 2008-10-14 DE DE602008005636T patent/DE602008005636D1/de active Active
- 2008-10-14 SG SG2011056447A patent/SG174043A1/en unknown
- 2008-10-14 CA CA2704360A patent/CA2704360A1/en not_active Abandoned
- 2008-10-14 SI SI200830183T patent/SI2205575T1/sl unknown
- 2008-10-14 WO PCT/US2008/079798 patent/WO2009058552A1/en not_active Ceased
- 2008-10-14 AT AT08843687T patent/ATE502022T1/de active
- 2008-10-14 SI SI200830775T patent/SI2295417T1/sl unknown
- 2008-10-14 BR BRPI0818837 patent/BRPI0818837A2/pt not_active IP Right Cessation
- 2008-10-14 PT PT10190591T patent/PT2295417E/pt unknown
- 2008-10-14 JP JP2010532118A patent/JP5460605B2/ja not_active Expired - Fee Related
- 2008-10-14 KR KR1020107009453A patent/KR20100075575A/ko not_active Withdrawn
- 2008-10-14 EP EP08843687A patent/EP2205575B1/en not_active Not-in-force
- 2008-10-14 PL PL08843687T patent/PL2205575T3/pl unknown
- 2008-10-14 EA EA201000714A patent/EA016447B1/ru not_active IP Right Cessation
- 2008-10-14 DK DK08843687.8T patent/DK2205575T3/da active
- 2008-10-14 EP EP12159802A patent/EP2471769A1/en not_active Withdrawn
- 2008-10-14 DK DK10190591.7T patent/DK2295417T3/da active
- 2008-10-14 NZ NZ584545A patent/NZ584545A/en not_active IP Right Cessation
- 2008-10-14 CN CN2008801240109A patent/CN101910141B/zh not_active Expired - Fee Related
- 2008-10-14 ES ES10190591T patent/ES2390042T3/es active Active
- 2008-10-14 SG SG2011056454A patent/SG174044A1/en unknown
- 2008-10-14 PT PT08843687T patent/PT2205575E/pt unknown
- 2008-10-30 AR ARP080104770A patent/AR069135A1/es unknown
- 2008-10-30 CL CL2008003271A patent/CL2008003271A1/es unknown
- 2008-10-31 PE PE2008001866A patent/PE20091394A1/es not_active Application Discontinuation
- 2008-10-31 TW TW097142279A patent/TW200927099A/zh unknown
-
2010
- 2010-04-27 CO CO10049723A patent/CO6270332A2/es not_active Application Discontinuation
- 2010-04-28 IL IL205406A patent/IL205406A0/en unknown
-
2011
- 2011-06-15 CY CY20111100570T patent/CY1112337T1/el unknown
- 2011-11-18 US US13/299,703 patent/US8350084B2/en active Active
-
2012
- 2012-09-04 HR HRP20120703AT patent/HRP20120703T1/hr unknown
- 2012-09-28 CY CY20121100889T patent/CY1113346T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069135A1 (es) | Compuesto de alfa-(n-sulfonamido) acetamida como un inhibidor de produccion de peptido beta amiloide | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| CL2007003583A1 (es) | Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. | |
| CL2008001215A1 (es) | Compuestos derivados de heterociclos nitrogenados condensados; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, dislipidemia, obesidad y alzheimer. | |
| BR112012011332A2 (pt) | agentes direcionados para gadd45beta | |
| CR8642A (es) | Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos | |
| CL2008000791A1 (es) | Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm | |
| CL2007001870A1 (es) | Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d | |
| CL2007002641A1 (es) | Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias. | |
| IL219915A0 (en) | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | |
| HN2008001720A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina | |
| CL2007003832A1 (es) | Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades. | |
| CL2008001960A1 (es) | Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide. | |
| CL2007002121A1 (es) | Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab | |
| CL2007000789A1 (es) | Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer. | |
| CL2007003191A1 (es) | Compuestos derivados de pirimido-piridona, inhibidores de las proteina quinasas; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como artritis, sindrome de colon irritable, sindrome disneico agudo del adulto, epoc y para el | |
| CL2008002411A1 (es) | Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras. | |
| BRPI0911203A2 (pt) | peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo. | |
| CL2007002689A1 (es) | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. | |
| CL2008000910A1 (es) | Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide. | |
| CL2008002162A1 (es) | Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras. | |
| CL2007001630A1 (es) | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| CL2007003038A1 (es) | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. | |
| CL2007002619A1 (es) | Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion. | |
| CL2007002511A1 (es) | Compuestos derivados de pirrolo[2,3-f]isoquinolina, inhibidores de cinasa-2; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |